Rigel Pharmaceuticals, Inc. (RIGL)
Stock Price:
$2.45 USD
-0.06 (-2.39%)
Updated Aug 14, 2020 10:49 AM EDT - Market open
Key Info
| Market Cap |
413.88M |
| Revenue (ttm) |
108.04M |
| Net Income (ttm) |
-25.02M |
| Shares Out |
168.93M |
| EPS (ttm) |
-0.15 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$2.45 |
| Previous Close |
$2.51 |
| Change ($) |
-0.06 |
| Change (%) |
-2.39% |
| Day's Open |
2.51 |
| Day's Range |
2.44 - 2.53 |
| Day's Volume |
651,374 |
| 52-Week Range |
1.23 - 5.24 |
More Stats
| Market Cap |
413.88M |
| Enterprise Value |
364.50M |
| Earnings Date (est) |
Nov 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
168.93M |
| Float |
168.41M |
| EPS (basic) |
-0.14 |
| EPS (diluted) |
-0.15 |
| FCF / Share |
-0.26 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
15.19M |
| Short Ratio |
0.50 |
| Short % of Float |
5.88% |
| Beta |
1.35 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
3.83 |
| PB Ratio |
6.68 |
| Revenue |
108.04M |
| Operating Income |
-25.74M |
| Net Income |
-25.02M |
| Free Cash Flow |
-42.95M |
| Net Cash |
49.38M |
| Net Cash / Share |
0.29 |
| Gross Margin |
5.09% |
| Operating Margin |
-23.82% |
| Profit Margin |
-23.20% |
| FCF Margin |
-39.75% |
| ROA |
-10.94% |
| ROE |
-35.37% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$7.14*
(191.43% upside)
Low
5.00
Current: $2.45
High
8.00
Target: 7.14
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 59.29 | 44.51 | 4.48 | 20.38 | 28.90 | 8.25 | 7.15 | 2.25 | 4.75 | 125 |
| Revenue Growth | 33.2% | 892.62% | -78% | -29.46% | 250.24% | 15.38% | 217.78% | -52.63% | -96.2% | - |
| Gross Profit | 58.38 | 44.22 | 4.48 | 20.38 | 28.90 | 8.25 | 7.15 | 2.25 | 4.75 | 125 |
| Operating Income | -69.09 | -72.68 | -78.88 | -69.65 | -51.69 | -91.15 | -89.45 | -99.36 | -86.37 | 35.32 |
| Net Income | -66.89 | -70.48 | -77.99 | -69.22 | -51.46 | -90.91 | -89.03 | -98.84 | -85.97 | 37.89 |
| Shares Outstanding | 167 | 161 | 126 | 94.39 | 88.43 | 87.66 | 87.29 | 74.97 | 63.33 | 52.06 |
| Earnings Per Share | -0.40 | -0.44 | -0.62 | -0.73 | -0.58 | -1.04 | -1.02 | -1.32 | -1.36 | 0.72 |
| Operating Cash Flow | -41.51 | -58.83 | -77.56 | -75.89 | -23.41 | -69.75 | -86.08 | -85.21 | -69.38 | 46.74 |
| Capital Expenditures | -1.46 | -1.11 | 0.57 | -0.72 | -0.49 | -0.18 | -1.21 | -3.36 | -2.30 | -3.56 |
| Free Cash Flow | -42.97 | -59.93 | -76.99 | -76.61 | -23.90 | -69.93 | -87.28 | -88.57 | -71.68 | 43.18 |
| Cash & Equivalents | 98.08 | 129 | 116 | 74.77 | 126 | 143 | 212 | 298 | 248 | 177 |
| Total Debt | 36.31 | - | - | - | - | - | - | - | - | 0.80 |
| Net Cash / Debt | 61.77 | 129 | 116 | 74.77 | 126 | 143 | 212 | 298 | 248 | 176 |
| Assets | 148 | 139 | 119 | 78.13 | 132 | 154 | 226 | 310 | 257 | 187 |
| Liabilities | 93.75 | 29.23 | 18.47 | 23.11 | 40.37 | 25.89 | 17.81 | 20.95 | 20.96 | 20.56 |
| Book Value | 53.82 | 110 | 101 | 55.03 | 91.38 | 128 | 208 | 289 | 236 | 166 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Rigel Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
163 |
| CEO |
Raul R. Rodriguez |
Stock Information
| Ticker Symbol |
RIGL |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: RIGL |
| IPO Date |
November 29, 2000 |
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Phase III clinical study for autoimmune hemolytic anemia. Its clinical programs also comprise R835, a proprietary molecule from its interleukin receptor associated kinase (IRAK) program, which is in Phase I clinical study for autoimmune and inflammatory diseases. The company has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to pursue research related to MDM2 inhibitors, a novel class of drug targets called ligases, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Tavalisse. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is based in South San Francisco, California.